Mississauga:Bayer Canada has announced a new partnership with Mint Pharmaceuticals Inc. for the distribution of ADALAT XL 30 mg tablets in Canada. This strategic collaboration took effect on September 3, 2025. “We are excited to partner with Mint Pharmaceuticals Inc., a company known for its commitment to quality and customer service,” said Viktoria Friedrich, Country President and General Manager at Bayer Inc., Pharmaceutical Division. “This partnership will enable us to leverage Mint’s extensive distribution network and expertise in the Canadian market, ensuring that ADALAT XL remains readily available to those who need it.” “Canadian patients and healthcare professionals depend on uninterrupted access to vital medicines, and that responsibility drives everything we do at Mint,” said Jaiveer Singh, Chief Executive Officer of Mint Pharmaceuticals Inc. “By partnering with Bayer, we are reinforcing our shared commitment to reliability, quality, and patient care. With a best-in-class supply chain built over the past 15 years, Mint is proud to bring that strength to the distribution of ADALAT XL, ensuring Canadians have seamless access to this trusted therapy.” ADALAT XL (nifedipine extended-release tablets) is indicated for the management of chronic stable angina and the management of mild to moderate essential hypertension. With this new partnership, Bayer Canada aims to enhance the accessibility and availability of ADALAT XL to healthcare providers and patients across Canada. Read also:Bayer new drug application for gadoquatrane accepted for review in China Mint Pharmaceuticals is a Canadian-owned and operated manufacturer of affordable generic medicines. In 2024, Mint launched its 100th molecule in Canada. The company has been recognized by Deloitte as one of Canada’s Best Managed Companies for seven consecutive years, achieving Platinum Club status in 2025, and is a member company of the Canadian Generic Pharmaceutical Association (CGPA). Read also:Bayer Gets CDSCO Committee Nod to Manufacture, Market Darolutamide 300 mg for mHSPC, PMS Study Mandated